ImmuseLC-Plasma (Lactococcus lactis strain Plasma)

Lactococcus lactis subsp. lactis JCM 5805 (strain Plasma)
Evidence Level
Moderate
3 Clinical Trials
4 Documented Benefits
3/5 Evidence Score

Heat-killed lactic acid bacterium uniquely shown to activate plasmacytoid dendritic cells (pDCs) — innate immune cells producing antiviral interferon. Meta-analysis of RCTs supports reduced cold-like symptom days.

Studied Dose 100 billion (10¹¹) heat-killed cells/day; yogurt 100 billion cells/100 g serving.
Active Compound Heat-killed (paraprobiotic/postbiotic) Lactococcus lactis strain Plasma cells.

Benefits

Plasmacytoid dendritic cell activation

LC-Plasma uniquely activates pDCs — the innate immune cells most specialized for antiviral defense. Both live and heat-killed forms induce IFN-α production. The meta-analysis confirmed significant pDC activation (CD86 and HLA-DR expression on pDCs) across multiple RCTs of healthy adults.

Reduced cold-like symptom days

A meta-analysis pooled data on common cold-like symptoms — sore throat, runny nose, cough, feverishness — and found a reduction in cumulative symptom days for the LC-Plasma group versus placebo. Foundational RCTs also reported fewer days of common cold-like symptoms during yogurt consumption.

Type I interferon induction

LC-Plasma is uniquely internalized by pDCs (via phagocytosis) and induces significant IFN-α production (73.8 ± 2.5 pg/mL at the recommended dose) — exceeding levels reported in serum of hospitalized COVID-19 patients. Other tested postbiotic strains showed no internalization or IFN-α response.

Postbiotic stability advantage

As a heat-killed paraprobiotic/postbiotic, LC-Plasma doesn't require cold-chain storage or live-cell viability. The activity is preserved through normal manufacturing and remains effective when incorporated into shelf-stable foods, beverages, and supplements — a practical advantage over conventional live probiotics for immune support.

Mechanism of action

1

TLR9 / pDC pathway activation

LC-Plasma is uniquely phagocytosed by plasmacytoid dendritic cells (pDCs) — a relatively rare immune cell population specialized for sensing viral nucleic acids and producing massive amounts of type I interferons. Most lactic acid bacteria activate myeloid DCs, not pDCs. LC-Plasma's distinctive cell wall components engage TLR9 and other intracellular pattern recognition receptors.

2

Type I interferon (IFN-α/β) cascade

Activated pDCs secrete IFN-α/β, which establish an antiviral state in surrounding cells: upregulating MHC class I, activating NK cells, priming cytotoxic T lymphocytes, and inducing antiviral effector proteins (PKR, OAS, Mx). This produces 'innate immune training' that primes defenses against viral pathogens including rhinovirus and coronaviruses.

3

Mucosal immune priming

Oral consumption of LC-Plasma provides direct contact with gut-associated lymphoid tissue (GALT), where pDCs can be activated and migrate to draining lymph nodes. This may explain the systemic immune effects from oral administration despite the heat-killed status precluding gut colonization.

Clinical trials

1
LC-Plasma Evidence Synthesis (Individual Participant Data)

Individual participant data pooled analysis (Frontiers in Immunology, doi:10.3389/fimmu.2025.1696989).

Clinical trials of oral LC-Plasma vs placebo in healthy adults. Searches through across PubMed, Cochrane, J-Dream III, UMIN-CTR, and ICTRP.

Significant LC-Plasma effects on pDC activity (CD86 and HLA-DR expression on pDCs in peripheral blood). Reduced cumulative number of days with common cold-like symptoms (sore throat, runny nose, cough, feverishness). Authors concluded oral LC-Plasma activates pDCs and mitigates common cold-like symptoms in healthy adults — strongest pooled evidence for the immune mechanism translating to clinical outcomes.

2
Foundational LC-Plasma Yogurt Clinical Trial

Randomized, placebo-controlled, double-blind trial (Sugimura, Jounai, Ohshio, Tanaka, Suwa, Clin Immunol 149(3):509-518).

Healthy adult volunteers consuming yogurt fermented with L. lactis JCM5805 (LC-Plasma) vs placebo yogurt for 12 weeks.

Yogurt containing LC-Plasma activated pDC activity in vivo (peripheral blood pDC CD86 and HLA-DR expression). Effect was greater in subjects with low baseline pDC activity. IFN production capacity increased from baseline. Common cold morbidity risk was suppressed in the LC-Plasma group vs placebo. Established the foundational case that LC-Plasma activates pDCs in humans, not just in vitro.

3
IFN-α Comparative Study — LC-Plasma Uniqueness

Comparative postbiotic mechanism study (2025).

Five commercially available postbiotic products containing heat-killed bacterial strains tested for pDC activation and IFN-α induction. Confocal Z-stack imaging used to confirm bacterial internalization.

Among 5 tested postbiotic strains, only LC-Plasma demonstrated significant internalization by pDCs and induced measurable IFN-α (73.8 ± 2.5 pg/mL at recommended dose). This effect was not observed with other strains, even at higher loads (1×10¹¹ cells). L. paracasei MCC1849 adhered to cell surface but was not internalized. IFN-α level induced by LC-Plasma exceeded serum levels in hospitalized COVID-19 patients, suggesting a meaningful antiviral immune contribution.

Side effects and drug interactions

Common Potential side effects

Generally very well-tolerated; heat-killed status removes most safety concerns associated with live probiotics.
Mild GI symptoms occasionally reported in early trials.
No serious adverse events reported in the published RCTs.
Theoretical: very rare hypersensitivity reactions to bacterial cell wall components.
Lactose-containing dairy carriers (yogurt, milk drinks) may cause symptoms in lactose-intolerant individuals — switch to capsule or lactose-free format.

Important Drug interactions

No documented clinically significant drug interactions in published trials.
Theoretical: as an immune activator, caution in patients on immunosuppressive medications (e.g., transplant recipients, autoimmune disease patients on biologics) — though no clinical concerns have been reported.
Antibiotics do not affect LC-Plasma efficacy because the cells are heat-killed; this is a key practical advantage over live probiotics.
Compatible with vaccines based on current evidence.

Frequently asked questions about ImmuseLC-Plasma (Lactococcus lactis strain Plasma)

What is LC-Plasma (Lactococcus lactis Plasma)?

LC-Plasma is a specific strain of Lactococcus lactis studied for immune support, notably for its proposed ability to activate plasmacytoid dendritic cells, a type of immune cell involved in the body's first-line defenses.

What is LC-Plasma used for?

It is studied mainly for immune support, including helping maintain resistance during periods of physical stress or seasonal challenges. It is used as a heat-treated (non-live) postbiotic in many products.

How much LC-Plasma should I take?

It is dosed to provide a set number of cells per day; follow the specific product's labeling. Because it is often used in a heat-treated form, refrigeration is usually not required.

Is LC-Plasma safe?

It is generally well tolerated. As an immune-supporting ingredient, those with autoimmune conditions or on immune-related medication may wish to check with a doctor.

What is ImmuseLC-Plasma?

Heat-killed lactic acid bacterium uniquely shown to activate plasmacytoid dendritic cells (pDCs) — innate immune cells producing antiviral interferon. Meta-analysis of RCTs supports reduced cold-like symptom days.

What is ImmuseLC-Plasma used for?

ImmuseLC-Plasma is researched primarily for Immune Support and Respiratory Health. LC-Plasma uniquely activates pDCs — the innate immune cells most specialized for antiviral defense. Both live and heat-killed forms induce IFN-α production.

What is the recommended dosage of ImmuseLC-Plasma?

The clinically studied dose is 100 billion (10¹¹) heat-killed cells/day; yogurt 100 billion cells/100 g serving. Always follow the product label and check with a healthcare provider for personal advice.

Is ImmuseLC-Plasma safe, and does it have side effects?

For most healthy adults, ImmuseLC-Plasma is well tolerated at studied doses. Reported effects can include: Generally very well-tolerated; heat-killed status removes most safety concerns associated with live probiotics. Mild GI symptoms occasionally reported in early trials. It may also interact with some medications. ImmuseLC-Plasma is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does ImmuseLC-Plasma interact with any medications?

Possible interactions include: No documented clinically significant drug interactions in published trials. Theoretical: as an immune activator, caution in patients on immunosuppressive medications (e.g. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for ImmuseLC-Plasma?

NutraSmarts rates the evidence for ImmuseLC-Plasma as Moderate (3 out of 5). It is backed by 3 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Kato Y, Kobayashi K, Kuramochi Y, Miyata T, Ushida Y, Hayamizu K. Lactococcus lactis strain Plasma activates plasmacytoid dendritic cells and mitigates common cold-like symptoms in healthy adults: a meta-analysis of individual participant data. Front Immunol. 2025;16:1696989. doi: 10.3389/fimmu.2025.1696989.PubMedUsed to support: Systematic review and meta-analysis concluding Lactococcus lactis strain Plasma activates plasmacytoid dendritic cells and reduces common-cold symptoms. The strongest synthesis behind the immune use.
  2. Sugimura T, Jounai K, Ohshio K, Tanaka T, Suwa M, Fujiwara D. Immunomodulatory effect of Lactococcus lactis JCM5805 on human plasmacytoid dendritic cells. Clin Immunol. 2013;149(3):509-18. doi: 10.1016/j.clim.2013.10.007.PubMedUsed to support: Randomized trial showing the immunomodulatory effect of L. lactis JCM5805 (strain Plasma) on human plasmacytoid dendritic cells. A controlled human trial behind the immune mechanism.
  3. Komano Y, Fukao K, Shimada K, Naito H, Ishihara Y, Fujii T, Kokubo T, Daida H. Effects of Ingesting Food Containing Heat-Killed Lactococcus lactis Strain Plasma on Fatigue and Immune-Related Indices after High Training Load: A Randomized, Double-Blind, Placebo-Controlled, and Parallel-Group Study. Nutrients. 2023;15(7):. doi: 10.3390/nu15071754.PubMedUsed to support: Randomized controlled trial in which heat-killed L. lactis strain Plasma improved fatigue and immune measures. Supports the immune and energy uses.
  4. Fujimura S, Kawamura M, Tamura Y. Lactococcus lactis Strain Plasma Uniquely Induces IFN-α Production via Plasmacytoid Dendritic Cell Activation: A Comparative Study of Postbiotic Products. Microorganisms. 2025;13(10):. doi: 10.3390/microorganisms13102261.PubMedUsed to support: Study showing L. lactis strain Plasma uniquely induces interferon-alpha via plasmacytoid dendritic cells. Mechanistic support for the antiviral and immune action.